EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY-NC-ND 4.0

From Visceral Pain to Emotional Distress: Comparative Effectiveness of Antispasmodics and Antidepressants in Irritable Bowel Syndrome – Systematic Review and Network Meta-analysis

Abdulrahman Ismaiel, Daniel-Corneliu Leucuta, Irina Boitos, Paul Foucambert, Mohamed Ismaiel, Stefan-Lucian Popa, Dan L Dumitrascu

Journal of Gastrointestinal and Liver Diseases · 17.07.2026

DOI: 10.15403/jgld-6815 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, online erschienen am 17.07.2026. Verfasst von Abdulrahman Ismaiel und 6 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Department of Internal Medicine, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. abdulrahman.ismaiel@yahoo.com. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims: Antispasmodics and antidepressants are standard therapies for managing both the gastrointestinal symptoms and psychological comorbidities associated with irritable bowel syndrome (IBS). However, direct comparative evidence regarding their efficacy across different symptom domains is scarce. This systematic review and network meta-analysis aimed to assess the relative effectiveness of these agents on abdominal pain, psychological outcomes, overall IBS symptom severity, and quality of life (QoL).

Methods

We conducted a comprehensive search of PubMed, EMBASE, and Scopus to identify relevant randomized controlled trials evaluating antispasmodics and antidepressants for IBS. Eligible studies underwent quality assessment and were synthesized using network meta-analysis. We calculated standardized mean differences (SMDs) with 95% confidence intervals (CIs) for pain outcomes (VAS), anxiety, depression, the IBS Severity Scoring System (IBS-SSS), and QoL.

Results

Twenty-nine studies were included in the analysis. Significant reductions in pain (VAS) were observed with imipramine (SMD -34.06; 95%CI -51.89 to -16.22) and the alverine/simethicone combination (SMD -6.23; 95%CI -9.93 to -2.53), while mebeverine and anise oil showed benefits in specific IBS subgroups. The most substantial improvements in anxiety occurred with flupentixol–melitracen (SMD -6.63; 95%CI -10.13 to -3.13), followed by small-intestinal release peppermint oil, fluoxetine, and vortioxetine. Imipramine was most effective for depressive symptoms (SMD -9.40; 95%CI -10.29 to -8.51), followed by venlafaxine, flupentixol–melitracen, desipramine, and vortioxetine. Amitriptyline was the only agent to show significant improvement in IBS-SSS scores (SMD -23.70; 95%CI -43.27 to -4.13). The largest gains in QoL were associated with otilonium bromide (SMD 30.90; 95%CI 26.62 to 35.18), followed by venlafaxine, amitriptyline, and cumin sofouf.

Conclusions

Imipramine and alverine/simethicone were superior for reducing abdominal pain, whereas flupentixol–melitracen, peppermint oil, fluoxetine, and vortioxetine demonstrated the strongest anxiolytic effects. Effective options for depression included imipramine, venlafaxine, flupentixol–melitracen, desipramine, and vortioxetine. Notably, amitriptyline uniquely improved overall IBS severity scores, while otilonium bromide, venlafaxine, amitriptyline, and cumin sofouf provided the greatest benefits for QoL. These findings clarify comparative efficacy and may guide tailored pharmacotherapy strategies for IBS patients.

Autor:innen und Institutionen

  • 2nd Department of Internal Medicine, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. abdulrahman.ismaiel@yahoo.com.
  • Department of Medical Informatics and Biostatistics, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania. dleucuta@umfcluj.ro.
  • Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania. irinaboitos@gmail.com.
  • Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore. paul.foucambert@gmail.com.
  • General Surgery Department, University Hospital Limerick, St Nessans Road, Dooradoyle, Limerick V94 F858, County Limerick, Ireland. dr.mohamed.sami.i@gmail.com.
  • 2nd Department of Internal Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania. popa.stefan@umfcluj.ro.

Zitieren

APA

Ismaiel, A., Leucuta, D. C., Boitos, I., Foucambert, P., Ismaiel, M., Popa, S. L., & Dumitrascu, D. L. (2026). From Visceral Pain to Emotional Distress: Comparative Effectiveness of Antispasmodics and Antidepressants in Irritable Bowel Syndrome – Systematic Review and Network Meta-analysis. Journal of Gastrointestinal and Liver Diseases. https://doi.org/10.15403/jgld-6815

Vancouver

Ismaiel A, Leucuta DC, Boitos I, Foucambert P, Ismaiel M, Popa SL, et al. From Visceral Pain to Emotional Distress: Comparative Effectiveness of Antispasmodics and Antidepressants in Irritable Bowel Syndrome – Systematic Review and Network Meta-analysis. Journal of Gastrointestinal and Liver Diseases. 2026. doi:10.15403/jgld-6815

BibTeX
@article{Ismaiel2026,
  author = {Ismaiel, Abdulrahman and Leucuta, Daniel-Corneliu and Boitos, Irina and Foucambert, Paul and Ismaiel, Mohamed and Popa, Stefan-Lucian and Dumitrascu, Dan L},
  title = {From Visceral Pain to Emotional Distress: Comparative Effectiveness of Antispasmodics and Antidepressants in Irritable Bowel Syndrome – Systematic Review and Network Meta-analysis},
  journal = {Journal of Gastrointestinal and Liver Diseases},
  year = {2026},
  doi = {10.15403/jgld-6815}
}
Kostenlos starten →